BCL2L1 and liver cancer: Moreover, both EST and SAGE results indicated that Bcl-xL was poorly expressed in normal liver, while abundant in other tissues (both normal and cancerous, data not shown), suggesting that this apoptotic regulator could constitute a good marker for liver cancer progression.